Company Interview / NeuroScientific makes impressive strides in Crohn's disease treatment

Key points:

NeuroScientific (ASX:NSB) shares rose 40% following positive Crohn’s disease treatment resultsStemSmart therapy is a stem cell product derived from bone marrow, targeting inflammationSpecial access data will support phase two clinical trials in Australia and the USAddressable market for stem cell therapies projected between $35 billion and $100 billion globally

Shares in NeuroScientific (ASX:NSB) surged nearly 40% following the announcement of positive clinical results for its Crohn’s disease therapy, StemSmart. CEO Nathan Smith reports the treatment, currently accessed by patients under a special access programme, has delivered significant improvement for individuals with visualising Crohn’s disease, a particularly severe form of the condition. Out of the initial four patients treated, three achieved strong positive results, with the fourth showing a partial response. The Stem smart product is a patented mesenchymal stem cell therapy derived from adult bone marrow, designed to target and reduce inflammation, and is prioritised for Crohn’s disease.

Smith outlines that data from the special access programme will inform a phase two clinical trial for Crohn’s disease in both Australia and the United States. The goal is to propel StemSmart towards commercialisation and possible partnerships for later-stage trials. NeuroScientific reportedly has funds to progress through to phase two trial initiation, but further capital raises are expected to support subsequent development.

Beyond Crohn’s disease, NeuroScientific holds early clinical trial data suggesting wider application of Stem smart in conditions such as kidney and lung transplantation, chronic obstructive pulmonary disease, and graft versus host disease. Smith highlights an estimated total addressable market for stem cell therapies ranging from $35 to $100 billion globally over the next decade.